Published: December 2021 | Report Code: LS10758 | Available Format: PDF | Pages: 539
The global chronic pain treatment market generated revenue of $80,766.6 million in 2020, and it is expected to grow at a CAGR of 7.2% during 2020–2030. The key factors responsible for the growth of the market include the increasing government support for such solutions, rising geriatric population, and surging prevalence of chronic health conditions.
Among people with pre-existing pain conditions, the COVID-19 pandemic created stress, accelerated the use of medications and substances, and caused disruptions in medical care. Moreover, screening procedures and diagnostic exams were severely restricted or postponed at hospitals and cancer care centers. However, the pandemic caused a sharp rise in the use of medications, including opioids, and non-steroidal anti-inflammatory drugs (NSAIDs), by patients. Thus, the market showed signs of resurgence during the second half of 2020, due to the re-opening of healthcare centres and increasing number of infusion appointments, which in turn is boosting the market for chronic pain treatment.
The drugs category accounted for a larger share of the chronic pain treatment market in 2020, based on product. This is mainly due to the increasing prevalence of various types of chronic pain, such as lower back pain, severe headache or migraine pain, and facial pain. Additionally, due to the growing geriatric population across the world, sedentary lifestyle, and rising number of surgical procedures, the market for the pain killer drugs is further expected to grow in the forecast period.
The musculoskeletal category held the largest share in the chronic pain treatment market in 2020, based on application. This is majorly attributed to the high prevalence of musculoskeletal disorders, such as osteoarthritis, fibromyalgia, and rheumatoid arthritis. As per Arthritis Research U.K., a charity organization focused on improving the lives of patients suffering from arthritis, 8.7 million people aged 45 years and over in the U.K. were treated for osteoarthritis in 2017.
The cancer pain category is projected to register the fastest growth during the forecast period, based on indication. As per the National Cancer Institute (NCI), cancer is among the leading causes of death worldwide. As of January 2019, there were an estimated 16.9 million cancer survivors in the U.S.; by 2040, the number of new cancer cases diagnosed per year is expected to rise to 29.5 million and the number of cancer-related deaths to 16.4 million. Thus, the rising number of cancer survivors is driving the market, as the disease causes long-lasting and, often, excruciating pain.
The direct mode category recorded a larger share in the in the market for chronic pain treatment in 2020 and it is projected to register faster growth during the forecast period, based on distribution channel. The growing emphasis of pharmaceutical drug and medical device manufacturers on direct distribution is the leading factor driving the growth of the market in this category. Direct distribution allows patients participating in clinical trials to receive treatments at home, increasing the treatment success rate.
The hospitals category is expected to grow at the highest growth rate in the market, during the forecast period, based on end user. Pain treatment practices are the most frequently performed in hospitals, particularly for post-surgical pain, where the cost of monitoring and the treatment of adverse effects create the high demand for pain treatment drugs and devices.
Geographically, North America generated the largest revenue in 2020 in the chronic pain treatment market, owing to the presence of developed healthcare infrastructure, high healthcare expenditure, and wide availability of advanced drugs and devices in the region.
On the other hand, the APAC market is expected to witness the fastest growth during the forecast period, mainly on account of the improving healthcare infrastructure, increasing per capita income, growing geriatric population, and rising prevalence of chronic pain in the region. According to the United Nations (UN) Department of Economic and Social Affairs report on world population aging, the number of geriatric people in Asia is expected to increase by two-fold, from 395 million in 2019 to 587 million by 2030. Geriatric people are highly susceptible to chronic pain conditions, such as arthritis, neuropathic disorders, and back pain, which, in turn, fuel the demand for drugs and devices to treat chronic pain.
The market players have been continuously investing in developing innovative products for chronic pain treatment. Innovation in wearable technology for the treatment of chronic pain is one of the key advancements in the chronic pain treatment market. For instance, NeuroMetrix Inc. launched its wearable technology for the treatment of chronic pain in September 2020. The product name is Quell, a wearable, transcutaneous electrical nerve stimulation (TENS) device for knee, foot, and leg pain users, who can personalize and manage therapy discreetly through the mobile application in iPhone and Android smartphones.
Moreover, several companies are currently focusing on developing non-opioid pain therapy treatment systems to target dorsal root ganglion (DRG). For instance, in November 2020, Abbott Laboratories launched IonicRF generator, a radiofrequency ablation device that uses heat to target specific nerves and prevent pain signals from reaching the brain. Similarly, in January 2021, Abbott Laboratories announced the launch of NeuroSphere myPath, a digital health application designed to track and report on patient-perceived pain relief and general well-being associated with spinal cord stimulation (SCS) or DRG therapy.
According to the World Health Organization (WHO), between 2015 and 2050, the proportion of the world's population over 60 years will nearly double from 12% to 22%. Moreover, the incidence of chronic pain amongst elderly people in nursing homes is very high, and has become a serious problem for care facilities. To treat this condition in the aged population, pharmacological, non-pharmacological (physical therapy such as exercise, foot orthotics, or patellar taping for knee osteoarthritis), and occupational therapies (joint protection education and assistive devices) are majorly used, which, in turn, has a positive influence on the chronic pain treatment market.
Globally, the rising prevalence of chronic diseases is one of the major healthcare burdens, which affect high-income as well as low- and middle-income countries. Some of the chronic diseases include osteoarthritis, cancer, fibromyalgia, sickle-cell anaemia, and autoimmune diseases (rheumatoid arthritis), which require therapeutic intervention for proper pain treatment. The impact of these diseases can be ascertained from the fact that cancer caused 10 million deaths in 2020, as reported by the WHO. Owing to the increasing prevalence of chronic diseases, several treatment options, such as medication, physiotherapy, psychological therapy, and others, are used widely, through which pain can be treated.
|Base Year (2020) Market Size||$80,766.6 Million|
|Market Size Forecast in 2030||$162,175.2 Million|
|Forecast Period CAGR||7.2%|
|Report Coverage||Market Trends, Drivers, and Restraints; Revenue Estimation and Forecast; Segmentation Analysis; Regional Breakdown; Impact of COVID-19; Companies’ Strategic Developments; Company Profiling|
|Market Size by Segments||By Product; By Indication; By Application; By Distribution Channel; By End User|
|Market Size of Geographies||U.S.; Canada; Germany; France; U.K.; Italy; Spain; Netherlands; Russia; Sweden; Switzerland; China; Japan; India; Australia; South Korea; Brazil; Mexico; South Africa; Saudi Arabia|
The chronic pain treatment industry is highly competitive, due to the presence of several key players. In recent years, players in the market have been involved in product launches, partnerships, and collaborations in order to attain a significant position. For instance:
The global chronic pain treatment market report offers comprehensive market segmentation analysis along with market estimation for the period 2015–2030.
Based on Product
Based on Indication
Based on Application
Based on Distribution Channel
Based on End User
In 2030, the value of the chronic pain treatment market will be $162,175.2 million.
Musculoskeletal is the largest category under the application segment of the chronic pain treatment industry.
The major chronic pain treatment market drivers are the increasing government support for chronic pain treatment, elevating geriatric population, and rising prevalence of chronic health conditions.
North America is the largest and APAC is the fastest-growing chronic pain treatment market.
Most chronic pain treatment market players are adopting product launches and collaborations strategies to sustain their business growth.
Get a bespoke market intelligence solution
Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws